its a medical necessity
Success with AOD-9604 therapy requires comprehensive physician supervision, accurate dosing and reconstitution techniques, strategic timing to maximize lipolytic effects, objective monitoring of body composition changes, and integration with proper nutrition and exercise foundations
It should never be attempted without medical guidance, particularly for compounded formulations where concentration variability is already a consideration
In people with type 2 diabetes, both the secretion and action are deficient of GLP-1
Vendor technical sheets and primary studies report selectivity over related methyltransferases and enzymes of the NAD salvage pathway [1,6,7]
Participants included adults with type 2 diabetes and obesity, stratified by cardiovascular risk, including established cardiovascular disease, NYHA class IIIII heart failure, or chronic kidney disease